Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Biohaven Therapeutics Ltd.
- Study ID
- NCT06603623
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- BHV-2100 — DRUGBHV-2100 75mg
- BHV-2100 — DRUGBHV-2100 150 mg
- Placebo — DRUGmatching placebo
Study Details
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Key Dates
- First listed
- Sep 19, 2024
- Start date
- Oct 10, 2024
- Status verified
- Feb 2026
- Primary completion
- Mar 24, 2025
- Completion
- Mar 28, 2025
Study Design
- Enrollment
- 647 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: BHV-2100 75 mg
- Experimental: BHV-2100 150 mg
- Placebo Comparator: Placebo
Primary Outcome Measure
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose [ Time Frame: 2 hours post-dose ]
Locations (60)
Find similar trials in Gilbert, AZ
Nationwide
By condition
By specialty
Related Studies
- Quality Improvement and Practice Based Research in Neurology Using the EMRPHASE4 · Enrolling By Invitation · Endeavor Health · Evanston, Illinois
- Pain Biomarker StudyPHASE1 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
- Objectively Diagnose and Monitor Treatment of Light SensitivityRecruiting · Randy Kardon · Iowa City, Iowa
- Mind Body Balance for Pediatric MigraineRecruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio